AbbVie (ABBV)
(Delayed Data from NYSE)
$181.22 USD
+1.78 (0.99%)
Updated Jan 3, 2025 04:00 PM ET
After-Market: $181.27 +0.05 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
AbbVie (ABBV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$205.63 | $240.00 | $165.00 | 14.60% |
Price Target
Based on short-term price targets offered by 27 analysts, the average price target for AbbVie comes to $205.63. The forecasts range from a low of $165.00 to a high of $240.00. The average price target represents an increase of 14.6% from the last closing price of $179.44.
Analyst Price Targets (27)
Find the top stocks with the greatest price target potential and Zacks Rank of 1 or 2
Broker Rating
AbbVie currently has an average brokerage recommendation (ABR) of 1.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 28 brokerage firms. The current ABR compares to an ABR of 1.65 a month ago based on 27 recommendations.
Of the 28 recommendations deriving the current ABR, 18 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 64.29% and 7.14% of all recommendations. A month ago, Strong Buy made up 62.96%, while Buy represented 7.41%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 18 | 18 | 17 | 17 | 14 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 8 | 8 | 8 | 8 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.63 | 1.63 | 1.65 | 1.65 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
12/5/2024 | Daiwa America | Narumi Nakagiri | Strong Buy | Hold |
11/22/2024 | SVB Securities | David Risinger | Hold | Strong Buy |
11/18/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
11/15/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
11/15/2024 | Atlantic Equities | Steven K Chesney | Strong Buy | Strong Buy |
11/12/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
11/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
11/6/2024 | Guggenheim Securities | Vamil Divan | Strong Buy | Strong Buy |
11/4/2024 | Argus Research Corp. | David A Toung | Not Available | Strong Buy |
10/31/2024 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
10/31/2024 | UBS | Trung Huynh | Hold | Hold |
10/30/2024 | Not Identified | Not Identified | Hold | Hold |
10/25/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
10/24/2024 | Berenberg Bank | Luisa Hector | Hold | Hold |
10/17/2024 | Not Identified | Not Identified | Not Available | Hold |
10/17/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
10/9/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
10/7/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
9/16/2024 | Not Identified | Not Identified | Hold | Hold |
8/30/2024 | William Blair | Matt Phipps | Not Available | Strong Buy |
7/30/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.63 |
ABR (Last week) | 1.63 |
# of Recs in ABR | 28 |
Average Target Price | $205.63 |
LT Growth Rate | 8.30% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 143 of 251 |
Current Quarter EPS Est: | 2.99 |
ABBV FAQs
AbbVie Inc. (ABBV) currently has an average brokerage recommendation (ABR) of 1.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 28 brokerage firms.
The average price target for AbbVie Inc. (ABBV) is $205.63. The current on short-term price targets is based on 13 reports.
The forecasts for AbbVie Inc. (ABBV) range from a low of $165 to a high of $240. The average price target represents a increase of $13.47 from the last closing price of $181.22.
The current UPSIDE for AbbVie Inc. (ABBV) is 13.47%
Based on short-term price targets offered by 27 analysts, the average price target for AbbVie comes to $205.63. The forecasts range from a low of $165.00 to a high of $240.00. The average price target represents an increase of 14.6% from the last closing price of $179.44.